07:23 AM EDT, 04/20/2026 (MT Newswires) -- Compass Pathways (CMPS) and other psychedelic shares were up in Monday premarket activity, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness.

The president ordered the US Food and Drug Administration Commissioner to offer commissioner's national priority vouchers to "appropriate"psychedelic drugs that have been given breakthrough therapy designations to treat serious mental illnesses, according to the executive order.

The executive order also directed the US Secretary of Health and Human Services to distribute $50 million through the Advanced Research Projects for Health program.

The US attorney general has also been directed to start reviews of "relevant"products upon successful completion of their phase 3 clinical studies so they can be rescheduled upon FDA approval.

Shares of Compass were up 26% in Monday premarket activity, while Clearmind Medicine (CMND) stock was up 64%, AtaiBeckley (ATAI) was 25% higher, Cybin (HELP) and GH Research (GHRS) were up 17 each%, and Definium Therapeutics (DFTX) shares were 12% higher. Psyence Biomedical (PBM) was also up 83%.